Company Preview Steve Berger, Development Director

1

Who We Are

Aptimmune develops and markets a

portfolio of revolutionary

Inactivated Mucosal Vaccines

for diseases of swine.

2

Focus and Pipeline

1

2

3

4

SPECIES

DISEASES

CORE TECHNOLOGIES

PRODUCT LAUNCHES

U.S. Direct Productivity Losses due to PRRSV

4

2011Total PRRSV

Losses:

$665 million

:Viral Respiratory Pathogens

UnaddressedMarket

78%

2015 Influenza

Vaccine Sales

$13 Million

UnaddressedMarket

56%

2015 PRRSV

Vaccine Sales

$53 Million

U.S. PRRSV U.S. Influenza

$120 million overall PRRSV

vaccine opportunity

$60 million overall Influenza

vaccine opportunity

$120 Million overall PRRSV vaccine opportunity

U.S. Direct Productivity Losses due to PRRSV

5

:

2011Total PRRSV

Losses:

$665 million

Viral Respiratory PathogensUnaddressed

Market78%

2015 Influenza

Vaccine Sales

$13 Million

UnaddressedMarket

56%

2015 PRRSV

Vaccine Sales

$53 Million

U.S. PRRSV U.S. Influenza

$120 million overall PRRSV

vaccine opportunity

$60 million overall Influenza

vaccine opportunity

$120 Million overall PRRSV vaccine opportunity

6

BARRICADESM Formulation Technology

7

The PROBLEM with current vaccines:

… 3 things needed to SOLVE the problem:

… to address this, we created a product that is:

High rate of virus mutation

Autogenous Responsive

IneffectiveDelivery

Mucosal Targeted

Live Virus Risks Inactivated Safe/Stable360 - 480 nm

++

ParticleAntigen

Adjuvant

Vaccine Formulation

Intranasal Delivery to Pig

VaccineProduction: BARRICADE™PRRSVAutogenous

PRRS Virus ZMAC – Porcine Alveolar

Macrophage

PRRSV Production on ZMAC

Nano-Particle PRRSV Antigen Adjuvant

Complex

VirusInactivation

8

Production Animal Vaccines – Call for Consistency

“Consistency is the true foundation of trust. Either keep your promises, or do not make them” – Roy T. Bennett

9

Key Characteristics Traditional Autogenous PRRS Barricade Formulation PRRS

Virus Isolation Inconsistent by strain Much more promiscuous substrate

Virus titer Highly variable and not measured Consistent and measured

Formulation and Route of administration

In combo (often) and unnatural Mono-valent and natural

Antigen uptake and processing By chance By design

Reasonable Evidence of Efficacy ?? Established*

*Autogenous product. Efficacy not established by USDA. Indicates non-regulated study observations only.

Swine VaccineCompetitive Position

Conventional Mucosal

Inactivated competitor

MLV/LIVE competitor

10

Preferential Uptake of Nanoparticle-Antigen Complex

Virus control

Fig. 9. PRRSV antigens entrapped nanoparticles engulfed by alveolar

macrophages (Mfs). Scanning electron micrographs of PLGA [poly (DL-lactide-co-

glycolide)] microspheres (nanoparticles). Confocal micrographs of PRRSV antigens

entrapped nanoparticles: (b) Nanoparticles both on the surface and inside pig alveolar

Mfs; (c) Mfs embedded with nanoparticles; (d) fluorochrome labeled PRRSV-N

protein (green) in the engulfed nanoparticles inside the alveolar Mfs.

(a) (b) (c) (d)

Nanoparticle-PRRSV Ags Killed-PRRSV Ags

PRRSV Uptake by ZMAC

11

Aptimmune’s vaccine delivers antigen to immune cells comparable to live virus without inducing cell death.

[Dwivedi and Renukaradhya (2012, PLoS One); Renukaradhya et al. (2015)]

Adjuvant Immune Stimulation Activity

0

2000

4000

6000

8000

10000

12000

14000

16000

ZMAC TNF-α Stimulation by Adjuvant

LAM (Lipoarabinomannan)

LPS (Lipopolysaccharides)

APA (Aptimmune Proprietary Adjuvant)

LAM LPS APA

12

Aptimmune’s proprietary adjuvant provides robust stimulation of immune cells.

BARRICADE™Formulation Technology:Early POC Study

13

0

20

40

60

80

100

Mock Vaccine Traditional AutogenousPRRSV IM

BARRICADE™ PRRSV POC Formulation

% o

f p

igs

wit

h v

iru

s in

th

eir

lun

gs

@ 2

1d p

ost

ch

all

en

ge

Aptimmune’s BARRICADE™ Formulation Technology provided superior virus clearance from lung versus mock & traditional autogenous PRRSV vaccines.

1.26x103 *

1.85x10 *

1.24x103 * * BAL = replicating virus titer for positive animals

Applicator Specifications

• 2ml adjustable dose vaccinator

syringe

• Nasal applicator

• Soft medical-grade tubing

• Hose armor spring

• 30mm uni-lock draw-off (clear)

• Heat-sealed bag

• Instructions - English

Top Market Influencers: Top 15 States, Top 50 Producers = 4 KAM & 2 PSV Staff

= Producer

= Key Account Manager

= Professional Services Veterinarian

15

BarricadeSM

Difference

Right PRRSV isolate every time

Revolutionary inactivated mucosalvaccine formulation

Reduce Viral Shed and Spread time to stabilization

Better productivity growth feed conversion

16

Our Expertise

Aaron Gilbertie President & CEO

Angela McFarlandCFO (Fractional)

Federico ZuckermannCSO & Founder

Steve Berger Development Director

17

LEADERSHIP TEAM EXPERIENCE

Aaron GilbertiePresident & CEO

Over 15 years of swine health sales and marketing experience

Angela McFarlandCFO (Fractional)

Over 10 years experience as a CFO;

facilitated successful business exit

Federico ZuckermannFounder

Professor of Immunology; 25 years experience in swine research

Steve Berger Development Director

30 years of USDA-CVB regulated biologics development/

manufacturing experience

Financial Projection

18

SERIES A

Development of BARRICADESM PRRSV Autogenous

Technology transfer to manufacturing

Produce first BARRICADESM PRRSV Autogenous serial

SERIES B ($6.0 Million. Closing early 2017)

US launch of BARRICADESM PRRSV Autogenous and BARRICADESM Flu Autogenous

Launch US Key Account Management and Professional Service Veterinarian team

Develop & launch commercially licensed PRRSV and swine flu products

$0

$1

$2

$3

$4

$5

$6

$7

$8

$9

$10

Sep-16 Sep-17 Sep-18 Sep-19 Sep-20

Mil

lio

ns

Cash

Capital Raised

Projected Revenue

Ba

se B

rea

k-e

ven

Po

int

(Ap

r-19

)

2020 Business Value: $127 Million

$25,538,198

Series A

Series B

Funding Partners

Fox Ventures, LLC

Midwest Angel Investors

19

20

Barricade Launched at American Association of Swine Veterinarians –Denver, CO – February 25, 2017!

Thank you